Pharmacotherapy of Bone Diseases
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 6974
Interests: researching on natural products to treat osteoporosis and fractures; osteoporosis and fractures; osteoclast; osteoblasts; ovariectomized osteoporosis animal model; femoral-fractured rat model; other bone-related diseases
Today, the prevalence of various metabolic bone diseases (osteopenia, osteoporosis, osteomalacia, rickets, etc.) is increasing due to the increase in life expectancy and healthy life expectancy through the development of medical technology and economic growth. In addition, the number of fracture patients is increasing due to an increase in the leisure population and traffic accidents. Recently, the importance of bone health has been emphasized and various therapeutic agents have been developed, but they have several limitations (such as the impossibility of long-term treatment due to side effects and high cost of the treatment). To overcome these limitations, deciphering the underlying cellular and molecular mechanisms that control the induction and improvement of bone diseases may help to lay a pharmacological basis for bone diseases. In this Special Issue, we hope to improve our understanding of the various ways of improving bone disease. We invite papers covering a variety of topics, from the discussion of new therapeutic mechanisms, to the proposal of chemical and botanical drugs that can improve various bone diseases, to nutritional recommendations to improve bone diseases.
Dr. Jae-Hyun Kim
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- metabolic bone disease
- bone metabolism
- chronic diseases
- human health and pharmacotherapy
- molecular and physiological mechanisms